Sonoma Competitors
| SNOA Stock | USD 2.83 0.08 2.91% |
Sonoma Pharmaceuticals vs Quoin Pharmaceuticals Correlation
Modest diversification
The correlation between Sonoma Pharmaceuticals and QNRX is 0.25 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sonoma Pharmaceuticals and QNRX in the same portfolio, assuming nothing else is changed.
Moving together with Sonoma Stock
Moving against Sonoma Stock
| 0.77 | PFE | Pfizer Inc | PairCorr |
| 0.76 | AMG | Amgen Inc | PairCorr |
| 0.72 | PFE | Pfizer Inc CDR | PairCorr |
| 0.71 | H6D | Haleon PLC Earnings Call Next Week | PairCorr |
| 0.7 | ELVN | Enliven Therapeutics | PairCorr |
Sonoma Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sonoma Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sonoma and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sonoma Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Sonoma Stock performing well and Sonoma Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sonoma Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CPHI | 3.78 | (1.21) | 0.00 | (3.18) | 0.00 | 6.67 | 29.10 | |||
| RADX | 5.64 | 1.06 | 0.12 | 1.15 | 7.54 | 6.15 | 193.18 | |||
| FLGC | 5.71 | (0.08) | 0.00 | 0.11 | 0.00 | 9.42 | 30.99 | |||
| EVOK | 4.68 | 2.00 | 0.65 | 0.58 | 1.67 | 6.93 | 130.92 | |||
| YCBD | 8.99 | 0.88 | 0.08 | (0.51) | 7.91 | 21.17 | 112.24 | |||
| BFRI | 3.44 | (0.42) | 0.00 | (0.11) | 0.00 | 6.76 | 34.13 | |||
| NBY | 13.66 | 0.80 | 0.06 | 0.23 | 15.86 | 33.70 | 158.53 | |||
| TCRT | 4.70 | 0.09 | 0.02 | 0.11 | 5.56 | 10.07 | 24.31 | |||
| MYNZ | 4.54 | (0.74) | 0.00 | (0.28) | 0.00 | 9.48 | 26.72 | |||
| QNRX | 7.07 | 0.65 | 0.06 | (0.42) | 8.34 | 18.69 | 77.47 |
Cross Equities Net Income Analysis
Compare Sonoma Pharmaceuticals and related stocks such as China Pharma Holdings, Radiopharm Theranostics, and Flora Growth Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPHI | (1.1 M) | 19.3 M | 4.6 M | (20 M) | (26 M) | (15.4 M) | (9.2 M) | (19.3 M) | (10.8 M) | (20.7 M) | (2.9 M) | (3.4 M) | (4 M) | (3.1 M) | (4.7 M) | (4.3 M) | (4 M) |
| EVOK | (2.4 M) | (2.4 M) | (2 M) | (2.8 M) | (13.2 M) | (12.1 M) | (10.7 M) | (12.2 M) | (7.6 M) | (7.1 M) | (13.2 M) | (8.5 M) | (8.2 M) | (7.8 M) | (5.4 M) | (4.8 M) | (5.1 M) |
| YCBD | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (3.4 M) | (1.7 M) | (412.1 K) | (45.4 M) | 12.6 M | (23.4 M) | (74.1 M) | (22.9 M) | (3.7 M) | (2 M) | (1.8 M) | (1.9 M) |
| BFRI | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (37.7 M) | (640 K) | (20.1 M) | (17.8 M) | (16 M) | (16.8 M) |
| NBY | (977 K) | (5.1 M) | (7 M) | (16 M) | (15.2 M) | (19 M) | (13.2 M) | (7.4 M) | (6.5 M) | (9.7 M) | (11 M) | (5.8 M) | (10.6 M) | (9.6 M) | (7.2 M) | (6.5 M) | (6.8 M) |
| TCRT | (72.5 K) | (63.8 M) | (96.1 M) | (57.1 M) | (31.8 M) | (120.1 M) | (165.3 M) | (54.3 M) | (53.1 M) | (117.8 M) | (78.8 M) | (78.8 M) | (37.7 M) | (35.1 M) | (4.7 M) | (4.2 M) | (4.4 M) |
| MYNZ | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (957.1 K) | (586.9 K) | (11.7 M) | (26.5 M) | (26.3 M) | (21.7 M) | (19.5 M) | (20.5 M) |
| QNRX | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | (2.6 M) | 15.3 M | 10.2 M | 15.3 M | (1.6 M) | (2.1 M) | (21.5 M) | (9.4 M) | (8.7 M) | (9 M) | (8.1 M) | (7.7 M) |
Sonoma Pharmaceuticals and related stocks such as China Pharma Holdings, Radiopharm Theranostics, and Flora Growth Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sonoma Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Sonoma Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Sonoma Pharmaceuticals Competitive Analysis
The better you understand Sonoma Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sonoma Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sonoma Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Sonoma Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Sonoma Pharmaceuticals Competition
Sonoma Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sonoma Pharmaceuticals in relation to its competition. Sonoma Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Sonoma Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sonoma Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sonoma Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Sonoma Pharmaceuticals position
In addition to having Sonoma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run FinTech Thematic Idea Now
FinTech
High long term potential financial entities that are ranging from payment processing, investment management to commercial and investment banking. The FinTech theme has 81 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize FinTech Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sonoma Pharmaceuticals Correlation with its peers. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sonoma Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 0.22 | Return On Assets | Return On Equity |
Investors evaluate Sonoma Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sonoma Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Sonoma Pharmaceuticals' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sonoma Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.